Castle Biosciences to announce Q3 2025 financial results on November 3, 2025, with a conference call at 4:30 p.m. ET.
Quiver AI Summary
Castle Biosciences, Inc. announced that it will release its third quarter and nine-month financial results for 2025 on November 3, following market close. The company's management will hold a conference call and webcast at 4:30 p.m. Eastern time that same day to discuss the results, with access options provided for participants. Castle Biosciences focuses on developing innovative diagnostic tests to improve patient care, currently offering tests for various cancers and other diseases, and is actively pursuing further developments in its research initiatives. Additional details about the company and its tests can be found on its website and social media platforms.
Potential Positives
- Castle Biosciences plans to discuss its financial results for Q3 2025, indicating transparency and commitment to communicating with investors.
- The company is actively engaged in research and development for innovative diagnostic tests, which may signal growth and expansion opportunities.
- Castle Biosciences highlights its focus on improving patient care, reinforcing its mission and potential competitive advantage in the healthcare diagnostics market.
Potential Negatives
- The press release does not provide any insights or performance metrics from the upcoming financial results, raising concerns about potential underperformance in the third quarter and first nine months of the year.
- The timing of the release and the conference call on November 3, 2025, may indicate a gap in communication with investors and stakeholders who are seeking timely updates on the company’s performance.
- The mention of ongoing research and development programs without specific details could imply a lack of immediate or tangible results in the pipeline, which may affect investor confidence.
FAQ
What are Castle Biosciences' financial results release dates?
Castle Biosciences will release its financial results for Q3 and nine months on November 3, 2025.
How can I access the financial results conference call?
You can access the conference call via a live webcast at https://events.q4inc.com/attendee/153584002 or by phone at 1 833 470 1428.
What time is the financial results conference call?
The conference call will take place at 4:30 p.m. Eastern time on November 3, 2025.
Will there be a Q&A session during the conference call?
Yes, there will be a brief Question and Answer session following the management commentary.
What is the focus of Castle Biosciences' tests?
Castle Biosciences focuses on innovative diagnostics for skin cancers, Barrett’s esophagus, and uveal melanoma.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CSTL Insider Trading Activity
$CSTL insiders have traded $CSTL stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $CSTL stock by insiders over the last 6 months:
- DEREK J MAETZOLD (Pres. & Chief Exec. Officer) has made 0 purchases and 19 sales selling 76,595 shares for an estimated $1,537,312.
- KRISTEN M OELSCHLAGER (Chief Operating Officer) has made 0 purchases and 2 sales selling 30,684 shares for an estimated $669,706.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CSTL Hedge Fund Activity
We have seen 84 institutional investors add shares of $CSTL stock to their portfolio, and 89 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 630,133 shares (+243.9%) to their portfolio in Q2 2025, for an estimated $12,867,315
- PARK WEST ASSET MANAGEMENT LLC removed 556,485 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $11,363,423
- BRAIDWELL LP added 457,488 shares (+125.3%) to their portfolio in Q2 2025, for an estimated $9,341,904
- WELLINGTON MANAGEMENT GROUP LLP removed 421,317 shares (-50.9%) from their portfolio in Q2 2025, for an estimated $8,603,293
- NUVEEN, LLC added 401,296 shares (+59.7%) to their portfolio in Q2 2025, for an estimated $8,194,464
- PRINCIPAL FINANCIAL GROUP INC added 331,101 shares (+22.6%) to their portfolio in Q2 2025, for an estimated $6,761,082
- UBS GROUP AG added 315,089 shares (+646.2%) to their portfolio in Q2 2025, for an estimated $6,434,117
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CSTL Analyst Ratings
Wall Street analysts have issued reports on $CSTL in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/09/2025
- Scotiabank issued a "Sector Outperform" rating on 05/21/2025
- Lake Street issued a "Buy" rating on 05/06/2025
To track analyst ratings and price targets for $CSTL, check out Quiver Quantitative's $CSTL forecast page.
$CSTL Price Targets
Multiple analysts have issued price targets for $CSTL recently. We have seen 3 analysts offer price targets for $CSTL in the last 6 months, with a median target of $37.0.
Here are some recent targets:
- Kyle Mikson from Canaccord Genuity set a target price of $37.0 on 09/09/2025
- Sung Ji Nam from Scotiabank set a target price of $40.0 on 05/21/2025
- Thomas Flaten from Lake Street set a target price of $35.0 on 05/06/2025
Full Release
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, after the close of market on Monday, Nov. 3, 2025.
Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day.
Conference Call and Webcast Details
A live webcast of the conference call can be accessed here:
https://events.q4inc.com/attendee/153584002
, or via the webcast link on the Investor Relations page of the Company’s website:
https://ir.castlebiosciences.com/overview/default.aspx
. Please access the webcast at least 10 minutes before the conference call start time. A replay of the webcast will be available following the conclusion of the conference call.
To access the live conference call via phone, please dial 1 833 470 1428 from the United States, at least 10 minutes prior to the start of the call, using the access code 735311. International dial-in numbers are available here: https://www.netroadshow.com/conferencing/global-numbers?confId=89205 ; please use the same access code above to join the call.
There will be a brief Question and Answer session following management commentary.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn , Facebook , X and Instagram .
DecisionDx-Melanoma, DecisionDx-CM Seq , i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
Investor Contact:
Camilla Zuckero
[email protected]
Media Contact:
Allison Marshall
[email protected]
Source: Castle Biosciences Inc.
